Quanterix Corp (NASDAQ:QTRX) Chairman Sells $164,017.02 in Stock

Quanterix Corp (NASDAQ:QTRX) Chairman E Kevin Hrusovsky sold 6,817 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $24.06, for a total value of $164,017.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

E Kevin Hrusovsky also recently made the following trade(s):

  • On Friday, March 1st, E Kevin Hrusovsky sold 1,903 shares of Quanterix stock. The shares were sold at an average price of $25.00, for a total value of $47,575.00.
  • On Friday, February 1st, E Kevin Hrusovsky sold 1,952 shares of Quanterix stock. The shares were sold at an average price of $20.90, for a total value of $40,796.80.
  • On Thursday, January 3rd, E Kevin Hrusovsky sold 1,949 shares of Quanterix stock. The shares were sold at an average price of $17.59, for a total value of $34,282.91.

NASDAQ:QTRX traded up $0.84 on Friday, hitting $22.75. The stock had a trading volume of 58,391 shares, compared to its average volume of 76,330. The firm has a market cap of $492.12 million, a P/E ratio of -15.91 and a beta of 1.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.95 and a current ratio of 3.28. Quanterix Corp has a 52 week low of $13.00 and a 52 week high of $26.48.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.17). The firm had revenue of $10.88 million during the quarter, compared to the consensus estimate of $9.69 million. Quanterix had a negative return on equity of 62.68% and a negative net margin of 83.80%. On average, equities analysts forecast that Quanterix Corp will post -1.44 earnings per share for the current fiscal year.

Several equities research analysts recently commented on QTRX shares. ValuEngine upgraded Quanterix from a “hold” rating to a “buy” rating in a research report on Thursday, January 31st. Canaccord Genuity restated a “buy” rating and set a $29.00 target price on shares of Quanterix in a research report on Friday, March 8th. Finally, Zacks Investment Research lowered Quanterix from a “hold” rating to a “sell” rating in a research report on Friday, January 25th.

A number of large investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA boosted its holdings in Quanterix by 5,803.2% in the first quarter. BNP Paribas Arbitrage SA now owns 1,830 shares of the company’s stock worth $47,000 after acquiring an additional 1,799 shares in the last quarter. TD Asset Management Inc. boosted its holdings in Quanterix by 4.1% in the fourth quarter. TD Asset Management Inc. now owns 47,700 shares of the company’s stock worth $873,000 after acquiring an additional 1,900 shares in the last quarter. Jennison Associates LLC boosted its holdings in Quanterix by 1.1% in the fourth quarter. Jennison Associates LLC now owns 297,563 shares of the company’s stock worth $5,448,000 after acquiring an additional 3,249 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of Quanterix by 116.7% in the fourth quarter. New York State Common Retirement Fund now owns 6,500 shares of the company’s stock worth $119,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Quanterix by 3,159.2% in the first quarter. Bank of Montreal Can now owns 3,911 shares of the company’s stock worth $101,000 after purchasing an additional 3,791 shares during the last quarter. Institutional investors and hedge funds own 51.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/quanterix-corp-qtrx-chairman-e-kevin-hrusovsky-sells-6817-shares.html.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Featured Article: What is a support level?

Insider Buying and Selling by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.